trial · primary record
Allogeneic Natural Killer Cell Line NK-92
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2027-05-31 |
| Primary endpoint | Progression free survival (PFS) time in C2C2 patients |
| Registry ID | NCT02727803 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:45:19.973Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02727803
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.